Ironwood Pharmaceuti (IRWD) Stock Price, Quote & News

Company Profile

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA na...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 621 7722

Fax: 617 494 0480

Website: ironwoodpharma.com

Address:

100 Summer Street, Suite 2300, Boston, United States

Bio_Invest101 Jul. 16 at 11:14 PM

$IRWD Not sure if any of you have posted this one talking about IRWD last week. https://beyondspx.com/article/ironwood-pharmaceuticals-navigating-transition-amidst-pipeline-setback-and-strategic-review-nasdaq-irwd

0 · Reply

valueforme Jul. 16 at 7:26 PM

$IRWD Zealand has dual GLP-1 / GLP-2 molecule that has recently showed interesting results in an early phase obesity trial https://www.globenewswire.com/news-release/2025/06/18/3101731/0/en/Zealand-Pharma-announces-positive-topline-results-from-28-week-Phase-1b-trial-with-GLP-1-GLP-2-receptor-dual-agonist-dapiglutide.html Abbvie has recently got access to Gubra's Dual Amylin and Calcitonin Receptor Agonist via the partnership deal https://news.abbvie.com/2025-03-03-AbbVie-and-Gubra-Announce-License-Agreement-to-Develop-an-Amylin-Analog-for-the-Treatment-of-Obesity It would be pretty logical for Abbvie to get access to GLP-2 asset like apraglutide as a way to not just receive phase 3 asset in SBS, but also as a way to consider combination Amylin+GLP-2 treatment for obesity. Abbvie is not in a hurry though. Patiently waiting

1 · Reply

MadMaverick Jul. 16 at 6:09 PM

$IRWD coming up on my scanner today, potential swing. Room to .85 next. Look for continued buying volume and any catalysts coming up!

0 · Reply

Bio_Invest101 Jul. 16 at 2:52 PM

$IRWD Who and when do we get the 2 big holders?

1 · Reply

revueltoL Jul. 16 at 7:09 AM

$IRWD are you, really? I thought you were a long timer here and this movement shouldn’t have surprised you..

1 · Reply

revueltoL Jul. 16 at 7:08 AM

$IRWD no one wants it. Forget ‘cheaper’… like Teeman said, the guy running this show wants to self-acknowledge his greatness by resurfacing laurels that were bestowed on him in error… trademark of a loser.

0 · Reply

VSTN Jul. 15 at 8:45 PM

$IRWD I’m surprised BP hasn’t been interested at these levels.

0 · Reply

valueforme Jul. 15 at 8:08 PM

$IRWD Someone wants it cheaper

0 · Reply

Bio_Invest101 Jul. 15 at 4:37 PM

$IRWD I call it BS. Somebody is hunting for more shares. IF there’s negative news such as Apra FDA meeting related then we should see SP going back down to $0.50s ranges. If you truly dump your shares then why do you even care about 0.001 ASK? Please dump it at $0.50-0.40

1 · Reply

Bio_Invest101 Jul. 15 at 3:44 PM

$IRWD FDA news?

0 · Reply

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

Apr 30, 2025, 4:25 PM EDT - 2 months ago

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Apr 25, 2025, 7:05 AM EDT - 2 months ago

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

Apr 22, 2025, 4:05 PM EDT - 3 months ago

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Apr 14, 2025, 2:19 PM EDT - 3 months ago

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

Apr 14, 2025, 7:00 AM EDT - 3 months ago

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Apr 10, 2025, 10:49 AM EDT - 3 months ago

Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth

Mar 27, 2025, 4:05 PM EDT - 3 months ago

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Mar 25, 2025, 8:30 AM EDT - 4 months ago

Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund

Feb 27, 2025, 11:21 AM EST - 4 months ago

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:00 AM EST - 5 months ago

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

Feb 20, 2025, 4:00 PM EST - 5 months ago

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Jan 29, 2025, 4:05 PM EST - 6 months ago

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

Jan 17, 2025, 8:07 AM EST - 6 months ago

Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications

Nov 26, 2024, 4:01 PM EST - 8 months ago

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 4:01 PM EST - 8 months ago

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Nov 7, 2024, 10:34 PM EST - 8 months ago

Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 9 months ago

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Oct 28, 2024, 7:00 AM EDT - 9 months ago

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

Oct 24, 2024, 4:00 PM EDT - 9 months ago

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Aug 29, 2024, 4:01 PM EDT - 11 months ago

Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Aug 9, 2024, 12:10 PM EDT - 1 year ago

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

Jul 25, 2024, 4:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call

Jun 28, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Starts Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Begin Conversation

Jun 26, 2024, 3:30 PM EDT - 1 year ago

The Schall Law Firm Initiates Inquiry Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Incurred Losses To Initiate Dialogue

Jun 25, 2024, 2:45 PM EDT - 1 year ago

The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Suffered Losses To Initiate Contact

Jun 24, 2024, 4:45 PM EDT - 1 year ago

The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Establish Communication

Jun 23, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors With Losses To Connect

Jun 22, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Reach Out

Jun 20, 2024, 1:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Jun 19, 2024, 4:20 PM EDT - 1 year ago

Allegations Against Ironwood Pharmaceuticals Inc The Schall Law Firm Initiates Probe And Urges Investors With Losses To Make Contact

Jun 18, 2024, 4:00 PM EDT - 1 year ago

Claims Against Ironwood Pharmaceuticals Inc The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Reach Out

Jun 11, 2024, 7:00 PM EDT - 1 year ago

Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Reach Out

Jun 9, 2024, 11:00 AM EDT - 1 year ago

Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Urges Investors With Losses To Contact Them

Jun 8, 2024, 11:00 AM EDT - 1 year ago

Allegations Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Initiates Probe And Invites Investors With Losses To Get In Touch

Jun 7, 2024, 3:00 PM EDT - 1 year ago

Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Contact Them

Jun 6, 2024, 1:00 PM EDT - 1 year ago

Accusations Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Initiates Investigation And Invites Investors With Losses To Reach Out

Jun 5, 2024, 1:30 PM EDT - 1 year ago

Ironwood Pharmaceuticals, Inc. Accusations: Schall Law Firm Announces Investigation and Calls for Investors with Losses to Connect

Jun 4, 2024, 3:00 PM EDT - 1 year ago

The Schall Law Firm Declares an Inquiry into Accusations Against Ironwood Pharmaceuticals, Inc. and Advocates for Investors with Losses to Reach Out

Jun 2, 2024, 11:00 AM EDT - 1 year ago

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

May 31, 2024, 6:15 PM EDT - 1 year ago

ONGOING INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

May 30, 2024, 4:01 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 21, 2024, 6:00 AM EDT - 1 year ago

Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

May 17, 2024, 12:45 PM EDT - 1 year ago

IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Bio_Invest101 Jul. 16 at 11:14 PM

0 · Reply

valueforme Jul. 16 at 7:26 PM

1 · Reply

MadMaverick Jul. 16 at 6:09 PM

$IRWD coming up on my scanner today, potential swing. Room to .85 next. Look for continued buying volume and any catalysts coming up!

0 · Reply

Bio_Invest101 Jul. 16 at 2:52 PM

$IRWD Who and when do we get the 2 big holders?

1 · Reply

revueltoL Jul. 16 at 7:09 AM

$IRWD are you, really? I thought you were a long timer here and this movement shouldn’t have surprised you..

1 · Reply

revueltoL Jul. 16 at 7:08 AM

0 · Reply

VSTN Jul. 15 at 8:45 PM

$IRWD I’m surprised BP hasn’t been interested at these levels.

0 · Reply

valueforme Jul. 15 at 8:08 PM

$IRWD Someone wants it cheaper

0 · Reply

Bio_Invest101 Jul. 15 at 4:37 PM

1 · Reply

Bio_Invest101 Jul. 15 at 3:44 PM

$IRWD FDA news?

0 · Reply

Peterson28 Jul. 15 at 3:39 PM

$IRWD Annoying low volume dump.

0 · Reply

mkmike396 Jul. 15 at 1:32 PM

$IRWD coming soon

0 · Reply

Vis_stock Jul. 14 at 9:52 PM

$IRWD

0 · Reply

valueforme Jul. 14 at 3:03 PM

$IRWD Researching the story of Miralax RX to OTC switching. Miralax is #1 OTC laxative brand as you know... https://www.biospace.com/schering-plough-corporation-enters-licensing-agreement-to-market-prescription-miralax-r-over-the-counter

1 · Reply

Peterson28 Jul. 14 at 12:32 PM

$IRWD Maybe it could consider turning into a crypto treasury company. It will immediately go up 1000%.

0 · Reply

Bio_Invest101 Jul. 14 at 6:24 AM

$IRWD Posted this one below “ we’ll be talking to FDA in coming weeks…”after the Citizens CC and now it’s like over 8 weeks long for this FDA meeting Tom spoke of fondly about. Results should come out soon at any days b4 Aug ER or if they delay the 2nd Q ER purposely in waiting for this “faster and shorter confirmatory ph3 design” news. Either ways it’s quiet time for the company rn. (the last second Q ER was on Aug 8 2024 ) Personally thinking IF, big if, FDA gives what Tom has asked for on Apra then the similarity of CMRX deal could play out again here, assuming the potential buyers are all lined up in anticipating the same FDA meeting news to decide on their best final offer sheets in cash and or the CVR amount… Hope for the best that Tom could finally let IRWD go to a better run company in 2025.

1 · Reply

Bio_Invest101 Jul. 13 at 8:08 PM

$IRWD OGs know Denner also owns big in AMRN and that’s why I mentioned its recent deal with Italy. IMO that deal 100% came from Denner control and approval. In May Citizens CC Tom stressed Launching Linzess OTC. If we could get CVS or Amazon to partner on OTC that will be huge in itself before we even talk about Apra and BO. But doesn’t that need ABBV to agree in some ways ? If IRWD can go it alone on OTC, How do they spilt the costs and profits ? Nothing at all? I always feel ABBV wouldn’t allow other BP to touch Linzess and IRWD as it’s a mature revenue cash cow. Welcome any opinion

1 · Reply

Bio_Invest101 Jul. 13 at 5:58 PM

$IRWD AMRN is Another small biotech that I am in with Denner being the top fund holder but deep in red. and he has got 100% AMRN BoD control 2 yrs ago. They did 1-20 RS in April. I feel Denner’s timing his moves now. Be prepared! https://www.globenewswire.com/news-release/2025/06/24/3104106/0/en/Amarin-Announces-Exclusive-License-and-Supply-Agreement-with-Recordati-to-Commercialize-VAZKEPA-Icosapent-Ethyl-in-Europe.html Amarin Announces Exclusive License and Supply Agreement

1 · Reply

Solaf Jul. 13 at 4:42 PM

$IRWD This is the worst-case scenario in my opinion. Given how incompetent the management is, they would almost certainly mishandle the approval process—and without Linzess revenue, the company could face bankruptcy. Knowing how bold and reckless they’ve been with such decisions in the past, I fear they might actually choose this path.

2 · Reply

valueforme Jul. 13 at 4:08 PM

$IRWD For entertainment purposes only

1 · Reply

Bio_Invest101 Jul. 13 at 3:57 PM

$IRWD If you’re true bull and long then stay focused on the developments since 4/14/25. You don’t have to like Tom nor believe everything he said. He’s the CEO trying to survive and recoup his own losses in money and reputation. None of us retails are in charge so stop whining. Retails are by products in WS to begin with unless you take yourself too seriously. Lately lots of M/A big and small deals happened. @$0.75 MC $120M? GS is 100% working on deals for us so they could make big bucks. You have to ask yourself: Am I ready if news breaks ? Look at the latest 3% Vanguard added shares reached over 10% 2nd to Denner’s holding which is still at $11.85; Armistice at $6.63 By 8/15 we shall know more. “Be greedy in bloody Street” My BO target Again: $5 +$3-5 CVR https://www.investing.com/news/transcripts/ironwood-at-the-citizens-jmp-life-sciences-conference-strategic-outlook-93CH-4029503 Ironwood at The Citizens JMP Life Sciences Conference: Strategic Outlook By Investing.com

1 · Reply

MoatHunter96 Jul. 13 at 1:00 PM

$IRWD remains focused on gastrointestinal therapies, with consistent revenue from its flagship product. While growth is modest, strong cash flow and strategic discipline make it a steady player in the biotech space.

0 · Reply

Market Cap	111.17M
Revenue (ttm)	351.41M
Net Income (ttm)	880,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	5.09
Profit Margin	0.25%
Debt to Equity Ratio	-1.15

Volume	1,502,600
Avg Vol	2,531,980
Day's Range	N/A - N/A
Shares Out	161.82M
Stochastic %K	46%
Beta	0.30
Analysts	Hold
Price Target	$0.92